Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 1, 2024ESMO OpenOpen Access

89P Predictors of real-world (rw) outcomes in patients (pts) with advanced/metastatic (a/m) non-small cell lung cancer (NSCLC) treated with pembrolizumab-based maintenance (MT)

View Full Paper
Ask AI
Bookmark
Share

Authors

VVVamsidhar VelchetiXSXuezheng SunJNJ. Nguyen

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Velcheti et al. (2024) studied this question.

synapsesocial.com/papers/68e76a1eb6db6435876df98fhttps://doi.org/10.1016/j.esmoop.2024.102668
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Predictors of outcomes in advanced non-small cell lung cancer treated with pembrolizumab maintenance.2025
  2. 2Real-World Outcomes of First-Line Pembrolizumab-Based Therapy in Advanced Non-Small-Cell Lung Cancer: A Retrospective Single-Center Study2026
  3. 3Frontline pembrolizumab monotherapy for metastatic non-small cell lung cancer with PD-L1 expression ≥50%: real-world outcomes in a US community oncology setting2024 · 3 citations
  4. 4Real-world outcomes and prognostic factors for immune checkpoint inhibitors in dMMR/MSI-H metastatic colorectal cancer (mCRC).2026
  5. 5Clinical Outcomes and Immune-Related Adverse Events in Metastatic Non-Squamous NSCLC Treated with First-Line Pembrolizumab–Chemotherapy: A Real-World Study from Serbia2026